BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018;48:1174-1185. [PMID: 30378141 DOI: 10.1111/apt.15005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma X, Xu H, Zhang D. Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis. BMJ Open 2021;11:e055182. [DOI: 10.1136/bmjopen-2021-055182] [Reference Citation Analysis]
2 Dal Buono A, Gabbiadini R, Solitano V, Vespa E, Parigi TL, Repici A, Spinelli A, Armuzzi A. Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy. Clin Exp Gastroenterol 2022;15:121-8. [PMID: 35909812 DOI: 10.2147/CEG.S350193] [Reference Citation Analysis]
3 Pugliese D, Guidi L, Privitera G, Bertani L, Tolusso B, Papparella LG, Maltinti S, Di Mario C, Onali S, Ceccarelli L, Rapaccini GL, Scaldaferri F, Gremese E, Gasbarrini A, Costa F, Armuzzi A. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. Expert Opin Biol Ther 2021;21:97-104. [PMID: 33074723 DOI: 10.1080/14712598.2020.1839045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Fiorino G, Danese S, Giacobazzi G, Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. Digestive and Liver Disease 2021;53:403-8. [DOI: 10.1016/j.dld.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00377-0. [PMID: 34856198 DOI: 10.1016/S2468-1253(21)00377-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
6 Lee JW. Ulcerative Colitis and Patient's Quality of Life, Especially in Early Stage. Gut Liver 2022;16:317-8. [PMID: 35551102 DOI: 10.5009/gnl220181] [Reference Citation Analysis]
7 Khalili H, Everhov ÅH, Halfvarson J, Ludvigsson JF, Askling J, Myrelid P, Söderling J, Olen O, Neovius M; SWIBREG Group. Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden. Aliment Pharmacol Ther 2020;52:655-68. [PMID: 32902894 DOI: 10.1111/apt.15889] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
8 Nishikawa Y, Sato N, Tsukinaga S, Uchiyama K, Koido S, Ishikawa D, Ohkusa T. Long-term outcomes of antibiotic combination therapy for ulcerative colitis. Ther Adv Chronic Dis 2021;12:20406223211028790. [PMID: 34285790 DOI: 10.1177/20406223211028790] [Reference Citation Analysis]
9 Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:5-23. [DOI: 10.1111/apt.15297] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
10 Rosenberg J, Steinberg JM, Mattar MC. Tofacitinib for the treatment of ulcerative colitis: A review of the literature. World J Meta-Anal 2019; 7(8): 373-379 [DOI: 10.13105/wjma.v7.i8.373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Mosli MH, Alamri AA, Saadah OI. Work and School Absenteeism in Inflammatory Bowel Disease Patients in Jeddah, Saudi Arabia: A Cross-Sectional Study. Saudi J Med Med Sci 2021;9:159-66. [PMID: 34084107 DOI: 10.4103/sjmms.sjmms_79_20] [Reference Citation Analysis]
12 Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2018;10:E1737. [PMID: 30424514 DOI: 10.3390/nu10111737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
13 Cluny NL, Nyuyki KD, Almishri W, Griffin L, Lee BH, Hirota SA, Pittman QJ, Swain MG, Sharkey KA. Recruitment of α4β7 monocytes and neutrophils to the brain in experimental colitis is associated with elevated cytokines and anxiety-like behavior. J Neuroinflammation 2022;19:73. [PMID: 35379260 DOI: 10.1186/s12974-022-02431-z] [Reference Citation Analysis]
14 Reinisch W, Sandborn WJ, Danese S, Hébuterne X, Kłopocka M, Tarabar D, Vaňásek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hoy M, Goetsch M, Bliss C, Gupta C, Cataldi F, Vermeire S. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. J Crohns Colitis 2021;15:938-49. [PMID: 33599720 DOI: 10.1093/ecco-jcc/jjab023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Helwig U, Kostev K, Schmidt C. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database. J Clin Gastroenterol 2021;55:e1-7. [PMID: 32011403 DOI: 10.1097/MCG.0000000000001323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhang J, Wu X, Wei S, Liu C, Wang X, Dong W. Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis. Autoimmunity. [DOI: 10.1080/08916934.2022.2103803] [Reference Citation Analysis]
18 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Horigome R, Sato H, Honma T, Terai S. Septicemic listeriosis during adalimumab- and golimumab-based treatment for ulcerative colitis: case presentation and literature review. Clin J Gastroenterol 2020;13:22-5. [DOI: 10.1007/s12328-019-01005-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Lair-mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-biroulet L, Simon M, Viennot S, Bouhnik Y. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Digestive and Liver Disease 2020;52:268-73. [DOI: 10.1016/j.dld.2019.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
21 Wang Z, Chen J, Chen Z, Xie L, Wang W. Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora. Saudi J Gastroenterol 2021;27:149-57. [PMID: 33835051 DOI: 10.4103/sjg.SJG_462_20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 AlRuthia Y, Almadi M, Aljebreen A, Azzam N, Alsharif W, Alrasheed H, Almuaythir G, Saeed M, HajkhderMullaissa B, Alharbi O. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia. J Med Econ 2020;23:1102-10. [PMID: 32619388 DOI: 10.1080/13696998.2020.1791889] [Reference Citation Analysis]
23 Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13622] [Reference Citation Analysis]
24 Colman RJ, Dhaliwal J, Rosen MJ. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Front Pediatr 2021;9:634739. [PMID: 33681110 DOI: 10.3389/fped.2021.634739] [Reference Citation Analysis]